Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Clin Transl Med. 2024 Sep;14(9):e1802. doi: 10.1002/ctm2.1802.
Recent studies have established the pivotal roles of patient-derived tumour organoids (PDTOs), innovative three-dimensional (3D) culture systems, in various biological and medical applications. PDTOs, as promising tools, have been established and extensively used for drug screening, prediction of immune response and assessment of immunotherapeutic effectiveness in various cancer types, including glioma, ovarian cancer and so on. The overarching goal is to facilitate the translation of new therapeutic modalities to guide personalised immunotherapy. Notably, there has been a recent surge of interest in the co-culture of PDTOs with immune cells to investigate the dynamic interactions between tumour cells and immune microenvironment. A comprehensive and in-depth investigation is necessary to enhance our understanding of PDTOs as promising testing platforms for cancer immunotherapy. This review mainly focuses on the latest updates on the applications and challenges of PDTO-based methods in anti-cancer immune responses. We strive to provide a comprehensive understanding of the potential and prospects of PDTO-based technologies as next-generation strategies for advancing immunotherapy approaches.
最近的研究已经确立了患者来源的肿瘤类器官（PDTOs）作为创新的三维（3D）培养系统在各种生物学和医学应用中的关键作用。PDTOs 作为有前途的工具，已经被建立并广泛用于各种癌症类型的药物筛选、免疫反应预测和免疫治疗效果评估，包括神经胶质瘤、卵巢癌等。总体目标是促进新治疗模式的转化，以指导个性化免疫治疗。值得注意的是，最近人们对 PDTO 与免疫细胞共培养的兴趣大增，以研究肿瘤细胞与免疫微环境之间的动态相互作用。需要进行全面和深入的研究，以提高我们对 PDTO 作为癌症免疫治疗有前途的测试平台的理解。这篇综述主要关注基于 PDTO 的方法在抗肿瘤免疫反应中的最新应用和挑战。我们努力提供对基于 PDTO 的技术作为推进免疫治疗方法的下一代策略的潜力和前景的全面理解。
